Author:
Rombouts Steffi J.,Walma Marieke S.,Vogel Jantien A.,van Rijssen Lennart B.,Wilmink Johanna W.,Mohammad Nadia Haj,van Santvoort Hjalmar C.,Molenaar I. Quintus,Besselink Marc G.
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791): 607–20.
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13.
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.
4. National Comprehensive Cancer Network. NCCN guidelines version 2.2015. Pancreatic adenocarcinoma. 2015. http://www.tri-kobe.org/nccn/guideline/pancreas/english/pancreatic.pdf . Accessed 15 Sep 2015.
5. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.
Cited by
125 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献